The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Live and Attenuated Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029
Synopsis
The global Live and Attenuated Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Live and Attenuated Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Live and Attenuated Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Live and Attenuated Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Live and Attenuated Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Live and Attenuated Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Live and Attenuated Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Live and Attenuated Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GlaxoSmithKline, Merck & Co., Pfizer, Inc, Astellas Pharma Inc and Johnson & Johnson, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Live and Attenuated Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Pediatric Vaccine
Adult Vaccines
Market segment by Application
Hospitals
Clinics
Diagnostic Centers
Research Institute
Others
Major players covered
GlaxoSmithKline
Merck & Co.
Pfizer, Inc
Astellas Pharma Inc
Johnson & Johnson
CSL Limited
Emergent BioSolutions, Inc.
MedImmune, LLC
Sanofi
Serum Institute
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Live and Attenuated Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Live and Attenuated Vaccine, with price, sales, revenue and global market share of Live and Attenuated Vaccine from 2018 to 2023.
Chapter 3, the Live and Attenuated Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Live and Attenuated Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Live and Attenuated Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Live and Attenuated Vaccine.
Chapter 14 and 15, to describe Live and Attenuated Vaccine sales channel, distributors, customers, research findings and conclusion.
The global Live and Attenuated Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Live and Attenuated Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Live and Attenuated Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Live and Attenuated Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Live and Attenuated Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Live and Attenuated Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Live and Attenuated Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Live and Attenuated Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GlaxoSmithKline, Merck & Co., Pfizer, Inc, Astellas Pharma Inc and Johnson & Johnson, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Live and Attenuated Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Pediatric Vaccine
Adult Vaccines
Market segment by Application
Hospitals
Clinics
Diagnostic Centers
Research Institute
Others
Major players covered
GlaxoSmithKline
Merck & Co.
Pfizer, Inc
Astellas Pharma Inc
Johnson & Johnson
CSL Limited
Emergent BioSolutions, Inc.
MedImmune, LLC
Sanofi
Serum Institute
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Live and Attenuated Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Live and Attenuated Vaccine, with price, sales, revenue and global market share of Live and Attenuated Vaccine from 2018 to 2023.
Chapter 3, the Live and Attenuated Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Live and Attenuated Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Live and Attenuated Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Live and Attenuated Vaccine.
Chapter 14 and 15, to describe Live and Attenuated Vaccine sales channel, distributors, customers, research findings and conclusion.
Index1 Market Overview
1.1 Product Overview and Scope of Live and Attenuated Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Live and Attenuated Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Pediatric Vaccine
1.3.3 Adult Vaccines
1.4 Market Analysis by Application
1.4.1 Overview: Global Live and Attenuated Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Diagnostic Centers
1.4.5 Research Institute
1.4.6 Others
1.5 Global Live and Attenuated Vaccine Market Size & Forecast
1.5.1 Global Live and Attenuated Vaccine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Live and Attenuated Vaccine Sales Quantity (2018-2029)
1.5.3 Global Live and Attenuated Vaccine Average Price (2018-2029)
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 GlaxoSmithKline Details
2.1.2 GlaxoSmithKline Major Business
2.1.3 GlaxoSmithKline Live and Attenuated Vaccine Product and Services
2.1.4 GlaxoSmithKline Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 GlaxoSmithKline Recent Developments/Updates
2.2 Merck & Co.
2.2.1 Merck & Co. Details
2.2.2 Merck & Co. Major Business
2.2.3 Merck & Co. Live and Attenuated Vaccine Product and Services
2.2.4 Merck & Co. Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Merck & Co. Recent Developments/Updates
2.3 Pfizer, Inc
2.3.1 Pfizer, Inc Details
2.3.2 Pfizer, Inc Major Business
2.3.3 Pfizer, Inc Live and Attenuated Vaccine Product and Services
2.3.4 Pfizer, Inc Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer, Inc Recent Developments/Updates
2.4 Astellas Pharma Inc
2.4.1 Astellas Pharma Inc Details
2.4.2 Astellas Pharma Inc Major Business
2.4.3 Astellas Pharma Inc Live and Attenuated Vaccine Product and Services
2.4.4 Astellas Pharma Inc Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Astellas Pharma Inc Recent Developments/Updates
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Live and Attenuated Vaccine Product and Services
2.5.4 Johnson & Johnson Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Johnson & Johnson Recent Developments/Updates
2.6 CSL Limited
2.6.1 CSL Limited Details
2.6.2 CSL Limited Major Business
2.6.3 CSL Limited Live and Attenuated Vaccine Product and Services
2.6.4 CSL Limited Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 CSL Limited Recent Developments/Updates
2.7 Emergent BioSolutions, Inc.
2.7.1 Emergent BioSolutions, Inc. Details
2.7.2 Emergent BioSolutions, Inc. Major Business
2.7.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product and Services
2.7.4 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Emergent BioSolutions, Inc. Recent Developments/Updates
2.8 MedImmune, LLC
2.8.1 MedImmune, LLC Details
2.8.2 MedImmune, LLC Major Business
2.8.3 MedImmune, LLC Live and Attenuated Vaccine Product and Services
2.8.4 MedImmune, LLC Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 MedImmune, LLC Recent Developments/Updates
2.9 Sanofi
2.9.1 Sanofi Details
2.9.2 Sanofi Major Business
2.9.3 Sanofi Live and Attenuated Vaccine Product and Services
2.9.4 Sanofi Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Sanofi Recent Developments/Updates
2.10 Serum Institute
2.10.1 Serum Institute Details
2.10.2 Serum Institute Major Business
2.10.3 Serum Institute Live and Attenuated Vaccine Product and Services
2.10.4 Serum Institute Live and Attenuated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Serum Institute Recent Developments/Updates
3 Competitive Environment: Live and Attenuated Vaccine by Manufacturer
3.1 Global Live and Attenuated Vaccine Sales Quantity by Manufacturer (2018-2023)
3.2 Global Live and Attenuated Vaccine Revenue by Manufacturer (2018-2023)
3.3 Global Live and Attenuated Vaccine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Live and Attenuated Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Live and Attenuated Vaccine Manufacturer Market Share in 2022
3.4.2 Top 6 Live and Attenuated Vaccine Manufacturer Market Share in 2022
3.5 Live and Attenuated Vaccine Market: Overall Company Footprint Analysis
3.5.1 Live and Attenuated Vaccine Market: Region Footprint
3.5.2 Live and Attenuated Vaccine Market: Company Product Type Footprint
3.5.3 Live and Attenuated Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Live and Attenuated Vaccine Market Size by Region
4.1.1 Global Live and Attenuated Vaccine Sales Quantity by Region (2018-2029)
4.1.2 Global Live and Attenuated Vaccine Consumption Value by Region (2018-2029)
4.1.3 Global Live and Attenuated Vaccine Average Price by Region (2018-2029)
4.2 North America Live and Attenuated Vaccine Consumption Value (2018-2029)
4.3 Europe Live and Attenuated Vaccine Consumption Value (2018-2029)
4.4 Asia-Pacific Live and Attenuated Vaccine Consumption Value (2018-2029)
4.5 South America Live and Attenuated Vaccine Consumption Value (2018-2029)
4.6 Middle East and Africa Live and Attenuated Vaccine Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Live and Attenuated Vaccine Sales Quantity by Type (2018-2029)
5.2 Global Live and Attenuated Vaccine Consumption Value by Type (2018-2029)
5.3 Global Live and Attenuated Vaccine Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Live and Attenuated Vaccine Sales Quantity by Application (2018-2029)
6.2 Global Live and Attenuated Vaccine Consumption Value by Application (2018-2029)
6.3 Global Live and Attenuated Vaccine Average Price by Application (2018-2029)
7 North America
7.1 North America Live and Attenuated Vaccine Sales Quantity by Type (2018-2029)
7.2 North America Live and Attenuated Vaccine Sales Quantity by Application (2018-2029)
7.3 North America Live and Attenuated Vaccine Market Size by Country
7.3.1 North America Live and Attenuated Vaccine Sales Quantity by Country (2018-2029)
7.3.2 North America Live and Attenuated Vaccine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Live and Attenuated Vaccine Sales Quantity by Type (2018-2029)
8.2 Europe Live and Attenuated Vaccine Sales Quantity by Application (2018-2029)
8.3 Europe Live and Attenuated Vaccine Market Size by Country
8.3.1 Europe Live and Attenuated Vaccine Sales Quantity by Country (2018-2029)
8.3.2 Europe Live and Attenuated Vaccine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Live and Attenuated Vaccine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Live and Attenuated Vaccine Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Live and Attenuated Vaccine Market Size by Region
9.3.1 Asia-Pacific Live and Attenuated Vaccine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Live and Attenuated Vaccine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Live and Attenuated Vaccine Sales Quantity by Type (2018-2029)
10.2 South America Live and Attenuated Vaccine Sales Quantity by Application (2018-2029)
10.3 South America Live and Attenuated Vaccine Market Size by Country
10.3.1 South America Live and Attenuated Vaccine Sales Quantity by Country (2018-2029)
10.3.2 South America Live and Attenuated Vaccine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Live and Attenuated Vaccine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Live and Attenuated Vaccine Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Live and Attenuated Vaccine Market Size by Country
11.3.1 Middle East & Africa Live and Attenuated Vaccine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Live and Attenuated Vaccine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Live and Attenuated Vaccine Market Drivers
12.2 Live and Attenuated Vaccine Market Restraints
12.3 Live and Attenuated Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Live and Attenuated Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Live and Attenuated Vaccine
13.3 Live and Attenuated Vaccine Production Process
13.4 Live and Attenuated Vaccine Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Live and Attenuated Vaccine Typical Distributors
14.3 Live and Attenuated Vaccine Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
